Clinical Trials Directory

Trials / Unknown

UnknownNCT05411250

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Peking University Cancer Hospital & Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

To explore the value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in early diagnosis of treatment-related cardiotoxicity (TACT) of lymphoma using visual method and semi-quantitative method.

Detailed description

First of all, the cardiac 18F-FDG uptake in patients with lymphoma will be observed by visual method: according to the uptake site, it will be divided into left ventricular uptake and biventricular uptake, and according to the degree of uptake, it will be divided into equal uptake (myocardial uptake is lower than cardiac blood pool uptake), moderate uptake (myocardial uptake is between cardiac blood pool uptake and liver uptake) and high uptake (myocardial uptake is higher than liver uptake). According to the uptake pattern, it can be divided into diffuse and segmental uptake.Then,using the region of interest method to mesure the value of myocardial uptake of 18F-FDG.The difference value of heart's SUVmax (Δ SUVmax- heart) and% Δ SUVmax- heart before and after chemotherapy or immunotherapy will be calculated. And SUVmax- heart / SUVmax- mediastinum ratio, SUVmax- heart / SUVmax- liver ratio and SUVmax- heart / SUVmax- background ratio (left gluteal muscle) after treatment. Taking the abnormality of ECG (early TACT) as the end point.

Conditions

Timeline

Start date
2022-06-01
Primary completion
2023-05-31
Completion
2023-07-31
First posted
2022-06-09
Last updated
2022-06-09

Source: ClinicalTrials.gov record NCT05411250. Inclusion in this directory is not an endorsement.